United Therapeutics | UTHR - Selling And Administration Expenses


United Therapeutics reported $184.1M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
Amarin USD 18.97M 1.03M Dec/2025
Ardelyx USD 101.44M 827K Jun/2026
Baxter International USD 730M 5M Sep/2026
Bayer EUR 4.02B 53M Sep/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
Biogen USD 752M 42.3M Sep/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
Halozyme Therapeutics USD 58.24M 1.24M Sep/2026
Insmed USD 253.03M 5.56M Sep/2026
Ionis Pharmaceuticals USD 154M 23.92M Sep/2026
J&J USD 6.25B 168M Sep/2026
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
Moderna USD 282M 66M Sep/2026
Omeros USD 11.32M 2.48M Sep/2024
Pfizer USD 3.28B 132M Sep/2026
PTC Therapeutics USD 80.63M 6.74M Jun/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
Teva Pharmaceutical Industries USD 1.01B 27M Sep/2026
United Therapeutics USD 184.1M 22.6M Sep/2026
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026